Since senescence could promote tumor development and contribute to therapy resistance [46, 54], the senescence induction upon Plk1 inhibition in tumor and normal cells could contribute to the moderate efficacy observed in patients treated with Plk1 inhibitors. Here, PLK1 is linked to neoplasm.